CoChat

Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas

Open access

The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.

Abstract

BACKGROUND: We explored whether spontaneous imaging tumor growth (estimated by the velocity of diametric expansion) and isocitrate dehydrogenase 1 (IDH1) mutation (estimated by IDH1 immunoexpression) were independent predictors of long-term outcomes of diffuse low-grade gliomas in adults. METHODS: One hundred thirty-one adult patients with newly diagnosed supratentorial diffuse low-grade gliomas were retrospectively studied. RESULTS: Isocitrate dehydrogenase 1 mutations were present in 107 patients. The mean spontaneous velocity of diametric expansion was 5.40 ± 5.46 mm/y. During follow-up (mean, 70 ± 54.7 mo), 56 patients presented a malignant transformation and 23 died. The median malignant progression-free survival and the overall survival were significantly longer in cases of slow velocity of diametric expansion (149 and 198 mo, respectively) than in cases of fast velocity of diametric expansion (46 and 82 mo; P < .001 and P < .001, respectively) and in cases with IDH1 mutation (100 and 198 mo, respectively) than in cases without IDH1 mutation (72 mo and not reached; P = .028 and P = .001, respectively). In multivariate analyses, spontaneous velocity of diametric expansion and IDH1 mutation were independent prognostic factors for malignant progression-free survival (P < .001; hazard ratio, 4.23; 95% CI, 1.81-9.40 and P = .019; hazard ratio, 2.39; 95% CI, 1.19-4.66, respectively) and for overall survival (P < .001; hazard ratio, 26.3; 95% CI, 5.42-185.2 and P = .007; hazard ratio, 17.89; 95% CI, 2.15-200.1, respectively). CONCLUSIONS: The spontaneous velocity of diametric expansion and IDH1 mutation status are 2 independent prognostic values that should be obtained at the beginning of the management of diffuse low-grade gliomas in adults.

Overview

Integrity signals

Registry

Crossref · 10.1093/neuonc/nou085

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 35 references

Cited by

See all 56

Metadata

Authors
Goze, C., Blonski, M., Le Maistre, G., Bauchet, L., Dezamis, E., Page, P., Varlet, P., Capelle, L., Devaux, B., Taillandier, L., Duffau, H., & Pallud, J.
Affiliations
Inserm (FR)
Venue
Neuro-Oncology
Published
2014-05-20
Volume
16
Issue
8
Pages
1100-1109
ISSN
  • 1522-8517 (ISSN-L)
  • 1523-5866
OpenAlex
W2111168085
Cited by
56
References
36
Citations by year
2025: 3 · 2024: 3 · 2023: 1 · 2022: 5 · 2021: 6 · 2020: 5 · 2019: 4 · 2018: 7 · 2017: 9 · 2016: 4 · 2015: 5 · 2014: 3
FWCI
3.51
Type
journal article
Language
en
Open access
Locations
  • Neuro-Oncology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Keywords
diffuse low-grade glioma, IDH1 mutation, tumor growth rate, prognostic factors, malignant transformation, progression-free survival, overall survival, adult glioma
MeSH terms
Adult, Aged, Brain Neoplasms, Female, Genetic Testing, Glioma, Humans, Isocitrate Dehydrogenase, Male, Middle Aged, Mutation, Prognosis, Retrospective Studies, Neoplasm Grading

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas. https://app.cochat.ai/papers/10.1093/neuonc/nou085
The paper
Goze, C., Blonski, M., Le Maistre, G., Bauchet, L., Dezamis, E., Page, P., Varlet, P., Capelle, L., Devaux, B., Taillandier, L., Duffau, H., & Pallud, J. (2014). Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas. Neuro-Oncology. https://doi.org/10.1093/neuonc/nou085

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.